Transfer Group Anti-infectives

Antibiotics are an essential part of modern medicine. They form the basis for the treatment of life-threatening bacterial and fungal infectious diseases. The Transfer Group Anti-infectives identifies new, promising active substances and systematically advances their development into innovative drugs.

The Transfer Group Anti-Infectives is an integral part of the InfectControl 2020 research network funded by the German Federal Ministry of Education and Research (BMBF). We receive further essential grants from the Free State of Thuringia and the German Centre for Infection Research (DZIF).

Team

Axel A. Brakhage

Acting Head

Details

Sina Gerbach

Deputy Head

Details

All employees

News from the team

Congratulations, François and Melanie! François and Melanie awarded in the 8th AMR Conference in Basel 03/08/2024 Read more

Xiretsa wins Stage II Funding: boosting a new class of Antibiotics Xiretsa, Inc is the second selected venture to receive INCATEs Stage II Funding. The €250k grant will allow the team to accelerate hit-to-lead activit… 02/12/2024 Read more

INCATE and BIOASTER join forces to improve support to AMR innovators INCATE (the INCubator for Antibacterial Therapies in Europe) and BIOASTER, the French Microbiology Technology Research Institute, have announced… 11/17/2023 Read more

All posts

Drug development

Antibiotics research and development unites many disciplines. From the discovery of a new natural bioactive compound or a new biological target structure to the drug, approximately 15 years of research and development time are required even under ideal conditions. A modern laboratory infrastructure and a closely interacting team of scientists from different disciplines are crucial for efficient compund development.

Projects

Infrastructure

Effective and goal-oriented antibiotics research and development are inextricably linked to modern instrumental laboratory analytics. Mass spectrometric methods, biophysical and spectroscopic methods are of global importance.

The Transfer Group Anti-infectives is equipped with an extensive modern equipment park, which was financed by various public sponsors. To view the individual devices, please select the tabs above.

News from the Leibniz-HKI

Research prizes for the Leibniz-HKI This fall, a veritable shower of prizes fell on the scientists of the Leibniz-HKI. Several prizes were awarded at this year's meetings of microbio… 10/20/2023 Read more

INCATE marks two-year anniversary INCATE (the INCubator for Antibacterial Therapies in Europe) has successfully reached its two-year milestone, boasting an impressive array of achievem… 09/07/2023 Read more

BMBF provides millions in funding for Thuringia's ATHANA alliance The RUBIN Alliance "ATHANA" (antifungal therapy approaches with nanoparticle-based targeting of drugs) is developing innovative therapeutic ap… 07/05/2023 | Press release Read more

News and press releases

Publications

Chalo DM, Franke K, Nchiozem-Ngnitedem VA, Kakudidi E, Origa-Oryem H, Namukobe J, Kloss F, Yenesew A, Wessjohann LA (2023) Prenylated isoflavanones with antimicrobial potential from the root bark of Dalbergia melanoxylon. Metabolites 13(6), 678.

Details

Eckhardt E, Li Y, Mamerow S, Schinköthe J, Sehl-Ewert J, Dreisbach J, Corleis B, Dorhoi A, Teifke J, Menge C, Kloss F, Bastian M (2023) Pharmacokinetics and efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside granulomas in the Guinea pig model. Antimicrob Agents Chemother 67(4), e0143822.

Details

Jia LJ, Rafiq M, Radosa L, Hortschansky P, Cunha C, Cseresnyés Z, Krüger T, Schmidt F, Heinekamp T, Straßburger M, Loeffler B, Doenst T, Lacerda JF, Campos A, Figge MT, Carvalho A, Kniemeyer O, Brakhage AA^# (2023) Aspergillus fumigatus hijacks human p11 to redirect fungal-containing phagosomes to non-degradative pathway. Cell Host Microbe 31(3), 373-388.e10.

Details